Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Carlsmed (CARL) Receivables - Net (2024 - 2026)

Carlsmed filings provide 2 years of Receivables - Net readings, the most recent being $11.4 million for Q4 2025.

  • On a quarterly basis, Receivables - Net rose 67.93% to $11.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.4 million, a 67.93% increase, with the full-year FY2025 number at $11.4 million, up 67.93% from a year prior.
  • Receivables - Net hit $11.4 million in Q4 2025 for Carlsmed, up from $11.3 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $11.4 million in Q4 2025 to a low of $6.8 million in Q4 2024.